Koyfin Home > Directory > Health Care > Amicus Therapeutics > Total Debt / (EBITDA-CAPEX)

Amicus Therapeutics Total Debt / (EBITDA-CAPEX) Chart (FOLD)

Amicus Therapeutics annual/quarterly Total Debt / (EBITDA-CAPEX) from 2010 to 2020.
  • Amicus Therapeutics Total Debt / (EBITDA-CAPEX) for the quarter ending March 03, 2020 was $-1m a 11.33% decrease of 0m year over year
  • Amicus Therapeutics Total Debt / (EBITDA-CAPEX) for the last 12 months ending March 03, 2020 was $-1m a 29.86% decrease of 0m year over year
  • Amicus Therapeutics Annual Total Debt / (EBITDA-CAPEX) for 2019 was $-1m a -40.09% increase of 0m from 2018
  • Amicus Therapeutics Annual Total Debt / (EBITDA-CAPEX) for 2018 was $-1m a 17.79% decrease of 0m from 2017
  • Amicus Therapeutics Annual Total Debt / (EBITDA-CAPEX) for 2017 was $-1m a -7.81% increase of 0m from 2016
Other Ratios Metrics:
  • Amicus Therapeutics Total Debt / Capital for the quarter ending September 09, 2018 was $44m a 27.22% increase of 12m year over year
  • Amicus Therapeutics Other Liabilities for the quarter ending December 12, 2018 was $39m a -4.44% decrease of -2m year over year
  • Amicus Therapeutics Total Debt / Equity for the quarter ending September 09, 2018 was $78m a 39.91% increase of 31m year over year
View Chart On Koyfin

Quarterly FOLD Total Debt / (EBITDA-CAPEX) Data

03/2020$-1m
12/2019$-1m
09/2019$-1m
06/2019$-1m
03/2019$-1m
12/2018$-1m
09/2018$-1m
06/2018$-1m
03/2018$-1m
12/2017$-1m

Annual FOLD Total Debt / (EBITDA-CAPEX) Data

2019$-1m
2018$-1m
2017$-1m
2016$-1m
2015$0m
2014$0m
2013$0m
2012$0m
2011$0m
2010$0m

Income Statement

Cost of Goods Sold
EBIT
EBITDA
Gross Profit
Net Income
Total Revenue

Balance Sheet

Altman Z-score
Cash and Short-Term Investments
Other Liabilities
Preferred Equity
Total Assets
Total Equity

Cash Flow

Capital Expenditures
Cash from Financing Activities
Cash from Investing Activities
Cash Flow from Operations
Levered Free Cash Flow (FCF)
Cash Acquisitions
Issuance of Common Stock
Repurchase of Common Stock
Debt Issued
Debt Repaid
Total Dividends Paid
Long-Term Debt
Long-Term Investments
Net Change in Cash

Valuation

Dividiend yield (D/Y)
Enterprise Value
EV / EBITDA (ntm)
EV / Sales (ntm)
EV / EBITDA (ltm)
EV / Sales (ltm)
Market Cap
Price / Book
Price / Earnings (ntm)
Price / Sales (ntm)
Price / Earnings (ltm)
Price / Sales (ltm)
Price / Tangible Book Value

Margins & Efficiency

EBITDA Margin
Gross Margin
Net Income Margin
Return on Assets %
Return on Capital %
Return on Equity %

Ratios

Total Debt / Capital
Total Debt / Equity
Net Debt / EBITDA
Total Debt / EBITDA
Total Debt / (EBITDA-CAPEX)
EBITDA / Interest Expenses
Long-Term Debt / Capital
Long-term Debt / Equity
Net Debt / (EBITDA-CAPEX)

Per Share

Diluted EPS Excl. Extra Items
Diluted EPS Incl. Extra Items
Diluted Shares Outstanding